Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 8/20 | 1.00 |
| ▸ | FUCA2 | Q9BTY2 | 1/20 | 0.95 |
| ▸ | GLA | P06280 | 3/20 | 0.65 |
| ▸ | AGL | P35573 | 2/20 | 0.65 |
| ▸ | GAA | P10253 | 2/20 | 0.65 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.65 |
| ▸ | GBA1 | P04062 | 1/20 | 0.65 |
| ▸ | MGAM | O43451 | 5/20 | 0.62 |
| ▸ | GANC | Q8TET4 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14268491 | 1.00 | FUCA1 (1.00) | FUCA1FUCA2GLAAGLGAA | |
| SCHEMBL9912298 | 1.00 | FUCA1 (1.00) | FUCA1FUCA2GLAAGLGAA | |
| SCHEMBL3443029 | 1.00 | FUCA1 (1.00) | FUCA1FUCA2GLAAGLGAA | |
| SCHEMBL2435958 | 1.00 | FUCA1 (1.00) | FUCA1FUCA2GLAAGLGAA | |
| SCHEMBL17178434 | 1.00 | FUCA1 (1.00) | FUCA1FUCA2GLAAGLGAA | |
| SCHEMBL15593238 | 1.00 | FUCA1 (1.00) | FUCA1FUCA2GLAAGLGAA | |
| SCHEMBL9343563 | 1.00 | FUCA1 (1.00) | FUCA1FUCA2GLAAGLGAA | |
| SCHEMBL17178435 | 1.00 | FUCA1 (1.00) | FUCA1FUCA2GLAAGLGAA | |
| SCHEMBL2437315 | 1.00 | FUCA1 (1.00) | FUCA1FUCA2GLAAGLGAA | |
| SCHEMBL1680180 | 1.00 | FUCA1 (1.00) | FUCA1FUCA2GLAAGLGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210228560-A1 | Combination of a Compound Having the Ability to Rearrange a Lysosomal Enzyme and Ambroxol and/or a Derivative of Ambroxol | CENTOGENE IP GMBH (DE) | 2021-07-29 | — | — | US | claimed |
| EP-2793872-B1 | COMBINATION OF A COMPOUND HAVING THE ABILITY TO REARRANGE A LYSOSOMAL ENZYME AND AMBROXOL AND/OR A DERIVATIVE OF AMBROXOL | CENTOGENE IP GMBH (DE) | 2021-03-10 | — | — | EP | claimed |
| US-20150258081-A1 | COMBINATION OF A COMPOUND HAVING THE ABILITY TO REARRANGE A LYSOSOMAL ENZYME AND AMBROXOL AND/OR A DERIVATIVE OF AMBROXOL | CENTOGENE IP GMBH (DE) | 2015-09-17 | — | — | US | claimed |
| EP-2793872-A1 | COMBINATION OF A COMPOUND HAVING THE ABILITY TO REARRANGE A LYSOSOMAL ENZYME AND AMBROXOL AND/OR A DERIVATIVE OF AMBROXOL | Centogene IP GmbH (DE) | 2014-10-29 | — | — | EP | claimed |
| WO-2013091897-A1 | COMBINATION OF A COMPOUND HAVING THE ABILITY TO REARRANGE A LYSOSOMAL ENZYME AND AMBROXOL AND/OR A DERIVATIVE OF AMBROXOL | CENTOGENE GMBH (DE) | 2013-06-27 | — | — | WO | claimed |
| US-20070021381-A1 | Stabilizing the mutant enzyme by administering a reversible competitive inhibitor consisting an iminosugar, 4-epi-isofagomine or 1-deoxygalactonojirimycin; Gaucher's disease; lysosomal storage diseases | MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY (US) | 2007-01-25 | — | — | US | claimed |
| US-6589964-B2 | Administering a competitive inhibitor of the enzyme in an amount effective to enhance enzyme activtiy, selected from 2,5-dideoxy- 2,5-imino-D-mannitol, 3,4-diepi- alpha -homonojirimycin, 5-O- deoxyglactonojirimycin, calystegines | MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY | 2003-07-08 | — | — | US | claimed |
| US-6583158-B1 | Competitive inhibitors of the enzymes, in particular imino sugars and related compounds | MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY | 2003-06-24 | — | — | US | claimed |
| US-12552736-B2 | Compositions for preventing and/or treating degenerative disorders of the central nervous system and/or lysosomal storage disorders | AMICUS THERAPEUTICS, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20220306568-A1 | Compositions For Preventing And/Or Treating Degenerative Disorders Of The Central Nervous System And/Or Lysosomal Storage Disorders | AMICUS THERAPEUTICS, INC. (US) | 2022-09-29 | — | — | US | disclosed |
| US-20220184185-A1 | MRNA BASED ENZYME REPLACEMENT THERAPY COMBINED WITH A PHARMACOLOGICAL CHAPERONE FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDERS | MODERNATX, INC. | 2022-06-16 | — | — | US | disclosed |
| US-11358926-B2 | Compositions for preventing and/or treating degenerative disorders of the central nervous system and/or lysosomal storage disorders | AMICUS THERAPEUTICS, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| US-20210228560-A1 | Combination of a Compound Having the Ability to Rearrange a Lysosomal Enzyme and Ambroxol and/or a Derivative of Ambroxol | CENTOGENE IP GMBH (DE) | 2021-07-29 | — | — | US | disclosed |
| EP-2793872-B1 | COMBINATION OF A COMPOUND HAVING THE ABILITY TO REARRANGE A LYSOSOMAL ENZYME AND AMBROXOL AND/OR A DERIVATIVE OF AMBROXOL | CENTOGENE IP GMBH (DE) | 2021-03-10 | — | — | EP | disclosed |
| US-20060100241-A1 | Preventing degradation of mutant enzymes associated with lysosomal storage diseases in mammalian cells | MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY (US) | 2006-05-11 | — | — | US | disclosed |
| US-6916829-B2 | Promoting the activity of glucocerebrosidease by administering a reversible competitive inhibitor such as iminosugars, e.g. calysegnines, isofagomines,N-C8-12-alkyl-deoxynojirimycins; lysosomal storage disorders | MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY (US) | 2005-07-12 | — | — | US | disclosed |
| US-20050113415-A1 | Promoting the activity of glucocerebrosidease by administering a reversible competitive inhibitor such as iminosugars, e.g. calysegnines, isofagomines,N-alkyl-deoxynojirimycins; lysosomal storage disorders | MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY (US) | 2005-05-26 | — | — | US | disclosed |
| US-6599919-B2 | Administering reversible competitive inhibitor of enzyme in an amount effective to enhance activity of enzyme in cell | MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY | 2003-07-29 | — | — | US | disclosed |
| US-6589964-B2 | Administering a competitive inhibitor of the enzyme in an amount effective to enhance enzyme activtiy, selected from 2,5-dideoxy- 2,5-imino-D-mannitol, 3,4-diepi- alpha -homonojirimycin, 5-O- deoxyglactonojirimycin, calystegines | MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY | 2003-07-08 | — | — | US | disclosed |
| US-6583158-B1 | Competitive inhibitors of the enzymes, in particular imino sugars and related compounds | MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY | 2003-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12552736-B2 | Compositions for preventing and/or treating degenerative disorders of the central nervous system and/or lysosomal storage disorders | GBA1, GALC, GBA2 | FUCA1 36/4885FUCA2 33/4885GLA 8/4885 |
| US-20210228560-A1 | Combination of a Compound Having the Ability to Rearrange a Lysosomal Enzyme and Ambroxol and/or a Derivative of Ambroxol | CMA1, MAN2B1, GBA3 | FUCA1 113/4885FUCA2 154/4885GLA 45/4885 |
| US-11358926-B2 | Compositions for preventing and/or treating degenerative disorders of the central nervous system and/or lysosomal storage disorders | GBA1, GALC, GAA | FUCA1 46/4885FUCA2 85/4885GLA 10/4885 |
| US-20220306568-A1 | Compositions For Preventing And/Or Treating Degenerative Disorders Of The Central Nervous System And/Or Lysosomal Storage Disorders | GBA1, GALC, GAA | FUCA1 46/4885FUCA2 85/4885GLA 10/4885 |
| US-20070021381-A1 | Stabilizing the mutant enzyme by administering a reversible competitive inhibitor consisting an iminosugar, 4-epi-isofagomine or 1-deoxygalactonojirimycin; Gaucher's disease; lysosomal storage diseases | GBA1, GBA2, GALC | FUCA1 42/4885FUCA2 77/4885GLA 24/4885 |
| US-20150258081-A1 | COMBINATION OF A COMPOUND HAVING THE ABILITY TO REARRANGE A LYSOSOMAL ENZYME AND AMBROXOL AND/OR A DERIVATIVE OF AMBROXOL | MAN2B1, CMA1, GBA1 | FUCA1 56/4885FUCA2 93/4885GLA 51/4885 |
| US-20050113415-A1 | Promoting the activity of glucocerebrosidease by administering a reversible competitive inhibitor such as iminosugars, e.g. calysegnines, isofagomines,N-alkyl-deoxynojirimycins; lysosomal storage disorders | GBA1, GAA, GBA2 | FUCA1 34/4885FUCA2 81/4885GLA 27/4885 |
| US-20060100241-A1 | Preventing degradation of mutant enzymes associated with lysosomal storage diseases in mammalian cells | GAA, CTSA, MAN2B1 | FUCA1 272/4885FUCA2 285/4885GLA 157/4885 |
| US-20220184185-A1 | MRNA BASED ENZYME REPLACEMENT THERAPY COMBINED WITH A PHARMACOLOGICAL CHAPERONE FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDERS | GAA, GBA1, GBA2 | FUCA1 15/4885FUCA2 26/4885GLA 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.